ATRC AtriCure Inc.

AtriCure to Announce First Quarter 2020 Financial Results

MASON, Ohio--(BUSINESS WIRE)--

(), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2020 financial results on Wednesday, April 29, 2020.

AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, April 29, 2020 to discuss its first quarter 2020 financial results. The call may be accessed through an operator by calling (844) 884-9951 for domestic callers and (661) 378-9661 for international callers using conference ID number 1753806. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure’s corporate website at . A replay of the presentation will be available for 90 days following the presentation.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit or follow us on Twitter .

EN
15/04/2020

Underlying

ATRCAtriCure Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AtriCure Inc.

 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure to Host Analyst & Investor Day on March 26, 2025

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expansion at our Analyst and Investor Day. We also look forward to bringing perspectives from key opinion leaders as well as sharing ...

March 12, 2025 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Resu...

MASON, Ohio--(BUSINESS WIRE)-- , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results. “2024 was another outstanding year at AtriCure, marked by continued progress on driving growth, improving profitability, and the introduction of several meaningful product launches across our key franchises,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “With the breadth and performance of our busi...

February 12, 2025 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Resul...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 financial results. Those interested in listening to the conference call should . Participants are encouraged to register more t...

January 22, 2025 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year ...

MASON, Ohio--(BUSINESS WIRE)-- , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025. Preliminary, unaudited revenue for fourth quarter 2024 is expected to be $124.3 million, reflecting growth of approximately 17% as r...

January 13, 2025 1 EN
 PRESS RELEASE
Free
ATRC ATRICURE INC.

AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conf...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. AtriCure’s management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at . About AtriCure AtriCure, I...

December 23, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch